Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.39 |
| ▸ | DAO | P14920 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5405012 | 0.86 | LMNA (0.41) | ALDH1A1LMNAMAPK1GRIA2GRIA4 | |
| SCHEMBL7355108 | 0.84 | NOTUM (0.34) | ALDH1A1LMNAMAPK1KEAP1NFE2L2 | |
| SCHEMBL740930 | 0.80 | NR1H2 (0.38) | ALDH1A1LMNAMAPK1GRIA2GRIA4 | |
| SCHEMBL2680797 | 0.79 | KDM4E (0.45) | ALDH1A1LMNAKDM4EKMT2AMEN1 | |
| SCHEMBL7248344 | 0.75 | DAO (0.57) | ALDH1A1KEAP1NFE2L2NOTUMDAO | |
| SCHEMBL3817485 | 0.75 | ALDH1A1 (0.36) | ALDH1A1LMNAMAPK1GRIA2GRIA4 | |
| SCHEMBL6970010 | 0.74 | ALDH1A1 (0.47) | ALDH1A1LMNAMAPK1KEAP1NFE2L2 | |
| SCHEMBL3605972 | 0.73 | NOTUM (0.43) | ALDH1A1KEAP1NFE2L2NOTUMDAO | |
| SCHEMBL13686294 | 0.72 | USP7 (0.35) | ALDH1A1LMNAGRIA2GRIA4KDM4E | |
| SCHEMBL5405617 | 0.71 | ALDH1A1 (0.53) | ALDH1A1LMNAMAPK1KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858898-B1 | HYDRAZINOCARBONYL-THIENO[2,3-C]PYRAZOLES, PREPARATION METHOD, COMPOSITIONS CONTAINING SAME AND USE | AVENTIS PHARMA SA (FR) | 2009-08-26 | — | — | EP | disclosed |
| EP-1858898-A1 | HYDRAZINOCARBONYL-THIENO[2,3-C]PYRAZOLES, PREPARATION METHOD, COMPOSITIONS CONTAINING SAME AND USE | Aventis Pharma S.A. (FR) | 2007-11-28 | — | — | EP | disclosed |
| US-20070179297-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-08-02 | — | — | US | disclosed |
| US-7238811-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-03 | — | — | US | disclosed |
| US-7179922-B2 | 4-Phenyloxypiperidionopiperidine compounds as antiinflammatory agents; autoimmune diseases; rheumatic diseases; cardiovascular disorders | ASTRAZENECA AB (SE) | 2007-02-20 | — | — | US | disclosed |
| WO-2006092510-A1 | HYDRAZINOCARBONYL-THIENO[2,3-C]PYRAZOLES, PREPARATION METHOD, COMPOSITIONS CONTAINING SAME AND USE | AVENTIS PHARMA S.A. (FR) | 2006-09-08 | — | — | WO | disclosed |
| US-20050171092-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-08-04 | — | — | US | disclosed |
| EP-1274701-B1 | [1,4']-BIPIPERIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| US-6903115-B2 | Bipiperidine compounds | ASTRAZENECA AB (SE) | 2005-06-07 | — | — | US | disclosed |
| EP-1493743-A1 | Substituted bipiperidine intermediates and derivatives thereof | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040014783-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-20040006080-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-6525070-B2 | For therapy of chemokine (such as CCR3) or H1 mediated disease state | ASTRAZENECA AB (SE) | 2003-02-25 | — | — | US | disclosed |
| EP-1274701-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-01-15 | — | — | EP | disclosed |
| US-20020077337-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2002-06-20 | — | — | US | disclosed |
| WO-2001077101-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077337-A1 | Chemical compounds | CCR3, CCR1, CCR4 | ALDH1A1 376/4885LMNA 4160/4885MAPK1 549/4885 |
| US-20050171092-A1 | Chemical compounds | CCR3, CCR1, CCR4 | ALDH1A1 428/4885LMNA 3860/4885MAPK1 697/4885 |
| US-20040006080-A1 | Chemical compounds | CCR3, CCR1, CCR4 | ALDH1A1 376/4885LMNA 4160/4885MAPK1 549/4885 |
| US-20040014783-A1 | Chemical compounds | CCR3, CCR1, CCR4 | ALDH1A1 376/4885LMNA 4160/4885MAPK1 549/4885 |
| US-20070179297-A1 | Chemical compounds | CCR3, CCR1, CCR4 | ALDH1A1 428/4885LMNA 3860/4885MAPK1 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.